Journal
BRAIN
Volume 138, Issue -, Pages 1738-1755Publisher
OXFORD UNIV PRESS
DOI: 10.1093/brain/awv081
Keywords
Alzheimer's disease; tauopathies; tau protein; microglia; neuroinflammation
Categories
Funding
- CurePSP [472-09]
- UNM CoBRE P30 Pilot Award
- UNM SOM RAC Award
- Alzheimer's Association [NIRG-11-204995]
- NIH/NINDS [R21NS077089, R01NS083704]
- Alzheimer's Association
- Bright Focus Foundation Pilot Award [AHAF0311KB]
- DOD (ERMS) [12109018]
- NIH [AG023012, NS074804, GM095426-02]
Ask authors/readers for more resources
Pathological aggregation of tau is a hallmark of Alzheimer's disease and related tauopathies. We have previously shown that the deficiency of the microglial fractalkine receptor (CX3CR1) led to the acceleration of tau pathology and memory impairment in an hTau mouse model of tauopathy. Here, we show that microglia drive tau pathology in a cell-autonomous manner. First, tau hyperphosphorylation and aggregation occur as early as 2 months of age in hTauCx3cr1(-/-) mice. Second, CD45(+) microglial activation correlates with the spatial memory deficit and spread of tau pathology in the anatomically connected regions of the hippocampus. Third, adoptive transfer of purified microglia derived from hTauCx3cr1(-/-) mice induces tau hyperphosphorylation within the brains of non-transgenic recipient mice. Finally, inclusion of interleukin 1 receptor antagonist (Kineret (R)) in the adoptive transfer inoculum significantly reduces microglia-induced tau pathology. Together, our results suggest that reactive microglia are sufficient to drive tau pathology and correlate with the spread of pathological tau in the brain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available